Euan Thomson

Summary

Euan is an operating partner at Khosla Ventures, where he focuses on healthcare. During his tenure at the firm, he has worked with Quanttus, CellScope, Zyomed, EyeNetra, Ginger.io, and Lumiata among many others. Euan currently serves as the interim CEO of Alivecor, which has developed a device that can turn any smartphone into a clinical-quality mobile heart monitor.

Previously, Euan trained as a physicist at the University of London, where he devoted more than fifteen years to research, teaching, clinical practice and administration within the United Kingdom’s health care system. In parallel, he formed a successful consultancy practice, providing advice for companies and hospitals on scientific development, product marketing and management with premier clients including Varian Medical Systems and Radionics, Inc., to name a few.

In 2002, Euan joined Accuray Inc., where he secured worldwide clinical acceptance for CyberKnife® Radiosurgery and dramatically improved their intellectual property portfolio. Further, he built distribution channels in more than 80 countries and executed a strategic sales alliance with Siemens Healthcare and consummated the successful acquisition of TomoTherapy®, Inc. At Accuray and, Photoelectron Inc., where he served as president and CEO, Euan initiated and directed a host of sophisticated financial transactions including private and public investments including initial public offerings.

Euan holds a bachelor’s of science degree in physics with medical applications, a master’s of science degree in radiation physics and a doctor of philosophy degree in physics from the University of London. He also has authored numerous scientific papers and holds six U.S. patents.

Euan is an operating partner at Khosla Ventures, where he focuses on healthcare. During his tenure at the firm, he has worked with Quanttus, CellScope, Zyomed, EyeNetra, Ginger.io, and Lumiata among many others. Euan currently serves as the interim CEO of Alivecor, which …

Euan is an operating partner at Khosla Ventures, where he focuses on healthcare. During his tenure at the firm, he has worked with Quanttus, CellScope, Zyomed, EyeNetra, Ginger.io, and Lumiata among many others. Euan currently serves as the interim CEO of Alivecor, which has developed a device that can turn any smartphone into a clinical-quality mobile heart monitor.

Prior to joining Khosla Ventures, Euan had more than 14 years of experience as a CEO, managing both public and private companies. As both a scientist and business professional, his commitment to innovation has enabled him to play pioneering roles with a number of breakthrough technologies.

Euan trained as a physicist at the University of London, where he devoted more than fifteen years to research, teaching, clinical practice and administration within the United Kingdom’s health care system. In parallel, he formed a successful consultancy practice, providing advice for companies and hospitals on scientific development, product marketing and management. Euan served premier clients including Varian Medical Systems and Radionics, Inc., to name a few. He also cultivated a specialty in development, positioning, regulatory approvals, pricing, and reimbursement of U.S. products for international markets.

In 2002, Euan joined Accuray Inc., which was then a small, privately held company. He directed its evolution from a latent promise to a global company and applied his foundation of science and technological expertise to secure worldwide clinical acceptance for CyberKnife® Radiosurgery through the creation of protocols and studies for treatment of tumors in the brain, spine, lung, liver, pancreas, prostate and breast. Moreover, Euan improved Accuray’s intellectual property portfolio from five issued U.S. patents in 2001 to 290 issued U.S. and foreign patents by the end of 2012. Euan expanded both the reach and scope of the organization and built distribution channels in more than 80 countries. He executed a strategic sales alliance with Siemens Healthcare and consummated the successful acquisition of TomoTherapy®, Inc. in 2011.

At Accuray and, Photoelectron Inc., where he served as president and CEO, Euan initiated and directed a host of sophisticated financial transactions including private and public investments including initial public offerings. Accuray’s successful 2007 IPO was priced above range and approximately 10-times oversubscribed. With the considerable business acumen he applied to his role at Accuray, he oversaw exponential revenue growth from $10 million in 2002 to more than $400 million in 2012.

Euan serves as a member of the board of directors of the Hospice of the Valley, a hospice facility based in San Jose, Calif. that serves individuals with life-limiting illnesses. He also has served as chair of the California division of the American Cancer Society’s business group, CEOs Against Cancer. Euan was awarded the Ernst and Young entrepreneur of the year award for northern California in the area of health and life sciences and also is a recipient of the ABBY Award for his innovation in biotechnology from the Adaptive Business Leaders Organization (ABL).

Euan holds a bachelor’s of science degree in physics with medical applications, a master’s of science degree in radiation physics and a doctor of philosophy degree in physics from the University of London. He also has authored numerous scientific papers and holds six U.S. patents.

More from Euan

Contact Euan